The Cancer of the Prostate Risk Assessment (CAPRA) in patients treated with external beam radiation therapy: Evaluation and optimization in patients at higher risk of relapse

Radiotherapy and Oncology

Volumn 101, Issue 3, 2011, Pages 513-520

  Halverson, Schuyler ^c   Schipper, Matthew ^c   Blas, Kevin ^c   Lee, Vivien ^c   Sabolch, Aaron ^c   Olson, Karin ^c   Sandler, Howard M ^a   Feng, Felix Y ^b,c   Hamstra, Daniel A ^c  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b VA ANN ARBOR HEALTHCARE SYSTEM   (United States)

^c UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Androgen deprivation therapy; External beam radiation therapy; Prostate cancer; Radical prostatectomy; Risk assessment

Indexed keywords

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER OF THE PROSTATE RISK ASSESSMENT; CANCER RELAPSE; CANCER RISK; CANCER SCREENING; CANCER SURGERY; COHORT ANALYSIS; EXTERNAL BEAM RADIOTHERAPY; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROCESS OPTIMIZATION; PROSTATE CANCER; PROSTATECTOMY; RADIATION DOSE FRACTIONATION; RETROSPECTIVE STUDY; RISK ASSESSMENT;

AGED; ANDROGEN ANTAGONISTS; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS;

EID: 81855183196     PISSN: 01678140     EISSN: 18790887     Source Type: Journal    
DOI: 10.1016/j.radonc.2011.05.080     Document Type: Article

References (43)

1. K. Akakura, S. Isaka, and S. Akimoto Long-term results of a randomized trial for the treatment of Stages B2 and C prostate cancer: radical prostatectomy versus external beam radiation therapy with a common endocrine therapy in both modalities Urology 54 1999 313 318
2. P.C. Albertsen,.J.A. Hanley, and J. Fine 20-year outcomes following conservative management of clinically localized prostate cancer JAMA 293 2005 2095 2101
3. A. Bill-Axelson, L. Holmberg, and F. Filen Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial J Natl Cancer Inst 100 2008 1144 1154
4. M. Bolla, T.M. de Reijke, and G. Van Tienhoven Duration of androgen suppression in the treatment of prostate cancer N Engl J Med 360 2009 2516 2527
5. M. Bolla, H. van Poppel, and L. Collette Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911) Lancet 366 2005 572 578
6. M. Bolla, G. Van Tienhoven, and P. Warde External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study Lancet Oncol 11 2010 1066 1073
7. M.K. Buyyounouski, A.L. Hanlon, E.M. Horwitz, and A. Pollack Interval to biochemical failure highly prognostic for distant metastasis and prostate cancer-specific mortality after radiotherapy Int J Radiat Oncol Biol Phys 70 2008 59 66
8. M.R. Cooperberg, S.J. Freedland, and D.J. Pasta Multiinstitutional validation of the UCSF cancer of the prostate risk assessment for prediction of recurrence after radical prostatectomy Cancer 107 2006 2384 2391
9. M.R. Cooperberg, D.J. Pasta, and E.P. Elkin The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy J Urol 173 2005 1938 1942
10. M.R. Cooperberg, A.J. Vickers, J.M. Broering, and P.R. Carroll Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer Cancer 116 2010 5226 5234
11. D.P. Dearnaley, M.R. Sydes, and J.D. Graham Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial Lancet Oncol 8 2007 475 487
12. J.W. Denham, A. Steigler, and C. Wilcox Time to biochemical failure and prostate-specific antigen doubling time as surrogates for prostate cancer-specific mortality: evidence from the TROG 96.01 randomised controlled trial Lancet Oncol 9 2008 1058 1068
13. J.W. Denham, A. Steigler, and C. Wilcox Why are pretreatment prostate-specific antigen levels and biochemical recurrence poor predictors of prostate cancer survival? Cancer 115 2009 4477 4487
14. S.J. Freedland, E.B. Humphreys, and L.A. Mangold Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy JAMA 294 2005 433 439
15. C. Giberti, L. Chiono, F. Gallo, M. Schenone, and E. Gastaldi Radical retropubic prostatectomy versus brachytherapy for low-risk prostatic cancer: a prospective study World J Urol 27 2009 607 612
16. M. Gonen, and G. Heller Concordance Probability adn Discriminatory Power In Proportional Hazards Regression Biometrika 92 2005 965 970
17. Hamstra DA, Bae K, Pilepich MV, et al. Older Age Predicts Decreased Metastasis and Prostate Cancer-Specific Death for Men Treated with Radiation Therapy: Meta-Analysis of Radiation Therapy Oncology Group Trials. Int J Radiat Oncol Biol Phys 2011; doi:10.1016/j.ijrobp.2010.07.2004.
18. E.M. Horwitz, K. Bae, and G.E. Hanks Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer J Clin Oncol 26 2008 2497 2504
19. A. Jemal, R. Siegel, J. Xu, and E. Ward Cancer statistics, 2010 CA Cancer J Clin 60 2010 277 300
20. M.W. Kattan, J.A. Eastham, A.M. Stapleton, T.M. Wheeler, and P.T. Scardino A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer J Natl Cancer Inst 90 1998 766 771
21. M.W. Kattan, M.J. Zelefsky, P.A. Kupelian, P.T. Scardino, Z. Fuks, and S.A. Leibel Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer J Clin Oncol 18 2000 3352 3359
22. L. Klotz Active surveillance for prostate cancer: a review Curr Urol Rep 11 2010 165 171
23. Kuban DA, Levy LB, Cheung MR, et al. Long-term Failure Patterns and Survival in a Randomized Dose-Escalation Trial for Prostate Cancer. Who Dies of Disease? Int J Radiat Oncol Biol Phys 2010.
24. D.A. Kuban, S.L. Tucker, and L. Dong Long-term results of the M.D. Anderson randomized dose-escalation trial for prostate cancer Int J Radiat Oncol Biol Phys 70 2008 67 74
25. W. Kwan, T. Pickles, and G. Duncan PSA failure and the risk of death in prostate cancer patients treated with radiotherapy Int J Radiat Oncol Biol Phys 60 2004 1040 1046
26. C.A. Lawton, M. DeSilvio, and M. Roach 3rd An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions Int J Radiat Oncol Biol Phys 69 2007 646 655
27. May M, Knoll N, Siegsmund M, et al. Validity of the CAPRA score to predict biochemical recurrence-free survival after radical prostatectomy. Results from a european multicenter survey of 1296 patients. J Urol 2007;178:1957-1962; discussion 1962.
28. A.A. Patel, M.H. Chen, A.A. Renshaw, and A.V. D'Amico PSA failure following definitive treatment of prostate cancer having biopsy Gleason score 7 with tertiary grade 5 JAMA 298 2007 1533 1538
29. D.F. Paulson, G.H. Lin, W. Hinshaw, and S. Stephani Radical surgery versus radiotherapy for adenocarcinoma of the prostate J Urol 128 1982 502 504
30. S.T.H. Peeters, W.D. Heemsbergen, and P.C.M. Koper Dose-Response in Radiotherapy for Localized Prostate Cancer: Results of the Dutch Multicenter Randomized Phase III Trial Comparing 68 Gy of Radiotherapy With 78 Gy J Clin Oncol 24 2006 1990 1996
31. M.V. Pilepich, K. Winter, and C.A. Lawton Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma-long-term results of phase III RTOG 85-31 Int J Radiat Oncol Biol Phys 61 2005 1285 1290
32. M. Roach 3rd, G. Hanks, and H. Thames Jr. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference Int J Radiat Oncol Biol Phys 65 2006 965 974
33. Sabolch A, Feng FY, Daignault-Newton S, et al. Gleason Pattern 5 is the Greatest Risk Factor for Clinical Failure and Death from Prostate Cancer after Dose-Escalated Radiation Therapy and Hormonal Ablation. Int J Radiat Oncol Biol Phys 2011.
34. M.J. Scolieri, A. Altman, and M.I. Resnick Neoadjuvant hormonal ablative therapy before radical prostatectomy: a review. Is it indicated? J Urol 164 2000 1465 1472
35. S.F. Shariat, P.I. Karakiewicz, C.G. Roehrborn, and M.W. Kattan An updated catalog of prostate cancer predictive tools Cancer 113 2008 3075 3099
36. Z. Symon, K.A. Griffith, P.W. McLaughlin, M. Sullivan, and H.M. Sandler Dose escalation for localized prostate cancer: substantial benefit observed with 3D conformal therapy Int J Radiat Oncol Biol Phys 57 2003 384 390
37. I.M. Thompson, C.M. Tangen, and J. Paradelo Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial J Urol 181 2009 956 962
38. B.J. Trock, C.C. Guo, M.L. Gonzalgo, A. Magheli, S. Loeb, and J.I. Epstein Tertiary Gleason patterns and biochemical recurrence after prostatectomy: proposal for a modified Gleason scoring system J Urol 182 2009 1364 1370
39. A. Widmark, O. Klepp, and A. Solberg Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial Lancet 373 2009 301 308
40. T. Wiegel, D. Bottke, and U. Steiner Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95 J Clin Oncol 27 2009 2924 2930
41. M.J. Zelefsky, J.A. Eastham, and A.M. Cronin Metastasis after radical prostatectomy or external beam radiotherapy for patients with clinically localized prostate cancer: a comparison of clinical cohorts adjusted for case mix J Clin Oncol 28 2010 1508 1513
42. K.H. Zhao, D.J. Hernandez, M. Han, E.B. Humphreys, L.A. Mangold, and A.W. Partin External validation of University of California, San Francisco, Cancer of the Prostate Risk Assessment score Urology 72 2008 396 400
43. A.L. Zietman, M.L. DeSilvio, and J.D. Slater Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial JAMA 294 2005 1233 1239